Beyond Appetite: An MBM-Based Hypothesis for Dual-Action Anti-Obesity Pharmacotherapy Targeting Both Sides of the Mass Balance Equation

1. Introduction: The Plateau Problem

The advent of highly effective GLP-1 receptor agonists has transformed obesity medicine. Semaglutide 2.4 mg produces a mean weight loss of approximately 15% from baseline, and the dual GIP/GLP-1 receptor agonist tirzepatide achieves losses approaching 20–25% [1,2]. These results have prompted widespread enthusiasm and a surge in pharmaceutical investment targeting novel incretin-based mechanisms.

Yet even these powerful agents encounter a familiar and frustrating problem: the weight loss plateau. After an initial period of rapid decline, the rate of weight loss progressively decelerates and eventually stabilizes, often at a body weight still well above the patient’s ideal therapeutic target [3]. In clinical trials of semaglutide, weight loss typically plateaus after approximately 60 weeks of treatment; with tirzepatide, the plateau occurs after roughly 72 weeks [1,2]. Continued pharmacotherapy maintains the reduced weight but does not produce further loss.

This plateau is conventionally attributed to “compensatory metabolic adaptation” – a vaguely defined set of counter-regulatory responses that the body mounts in defense of its pre-treatment weight [4]. The energy balance model (EBM), within which virtually all anti-obesity drug development has been conducted, offers no principled explanation for why this adaptation occurs, what its magnitude should be, or how it might be overcome. The plateau is treated as an empirical nuisance rather than a predictable physical phenomenon.

The mass balance model (MBM) provides a more precise framework for understanding the plateau – and, crucially, for designing interventions that transcend it. In this hypothesis article, I argue that the weight loss plateau is not a mystery, but a direct physical consequence of targeting only one side of the mass balance equation. I propose a rational, MBM-based combination pharmacotherapy that addresses both sides simultaneously, and I identify specific molecular targets capable of implementing this strategy.

2. The MBM Perspective: The Plateau Is a Physical Necessity

The MBM expresses body mass change as the difference between two independently measurable mass flows [5,6]:

$${\displaystyle \frac{dM}{dt}}=NMI-NMO$$

(1)

where NMI is net mass inflow (food and beverage mass minus excreted water) and NMO is net mass outflow (exhaled carbon as CO₂ plus urinary nitrogen and fecal losses minus inhaled O₂). All terms are in grams per day.

Under free-living conditions, NMO has been demonstrated to follow a relationship analogous to Torricelli’s Law of fluid dynamics [7]:

$$NMO=k\cdot M^{\left\{{\displaystyle \frac{1}{2}}\right\}}$$

(2)

where k is the mass clearance coefficient (kg^0·5/day), a directly measurable physiological parameter that quantifies the body’s efficiency in eliminating mass.

The history of medical progress is replete with transformative advances that occurred when biological phenomena were reframed through rigorous physical principles. Starling’s Law of the Heart transformed cardiology by treating the heart as a mechanical pump governed by preload rather than vague “vital forces.” The Goldman-Hodgkin-Katz voltage equation brought quantitative precision to neurophysiology by modeling ion fluxes as electrochemical driving forces. Fick’s principle enabled direct measurement of cardiac output, and Poiseuille’s Law underpins our understanding of vascular resistance. These models did not merely describe observations – they predicted them, revealed causal mechanisms, and guided therapy.

The MBM belongs to this distinguished tradition. By applying the fundamental principle of conservation of mass – expressed in grams per day rather than kilocalories – the MBM replaces the energy balance model’s reliance on abstract energy and ill-defined compensatory mechanisms with directly measurable mass flows (NMI and NMO) and a physically grounded clearance coefficient k. Just as Starling’s Law rendered “cardiac weakness” quantifiable and actionable, the MBM transforms the mysterious weight-loss plateau into a predictable consequence of Torricelli-like dynamics and adaptive changes in k. This shift from metaphorical energy accounting to literal mass accounting offers the same clarity and predictive power that physics-based models have repeatedly delivered to other fields of medicine.

2.1. How GLP-1 Agonists Work – in MBM Terms

GLP-1 receptor agonists, including semaglutide and tirzepatide, act primarily on the central nervous system to reduce appetite and on the gastrointestinal tract to delay gastric emptying [8]. In MBM terms, their dominant effect is a reduction in NMI: less food mass enters the body. This is sufficient to produce substantial weight loss, as Equation (1) becomes transiently negative.

2.2. Why the Plateau Occurs – in MBM Terms

However, Equation (2) reveals why NMI reduction alone cannot produce indefinite weight loss. As body mass (M) declines, NMO also declines – not because the body “adapts” in any mysterious sense, but because the physical driving force for mass elimination scales with the square root of body mass. This is Torricelli’s Law: a shrinking body sheds mass more slowly, just as a draining water tank empties more slowly as the water level falls [7].

Furthermore, the mass clearance coefficient (k) itself is not fixed. During prolonged caloric restriction or fasting, k decays toward a lower steady-state value, reflecting a genuine down-regulation of the body’s mass clearance machinery [7]. This is the molecular basis of what EBM terms “adaptive thermogenesis.” The progressive decline in both M (via Torricelli’s Law) and k (via metabolic adaptation) causes NMO to fall until it once again equals the now-reduced NMI. At this point, a new steady state is reached: the plateau.

To illustrate: consider a 100-kg individual with a baseline k of 0.20 kg^0·5/day. At this body mass, NMO is 2.0 kg/day. If semaglutide reduces NMI from 2.0 to 1.5 kg/day, weight loss begins. However, when body mass reaches 80 kg, NMO has fallen to 1.79 kg/day. When body mass reaches 70 kg, NMO has fallen to 1.67 kg/day. At approximately 56 kg, NMO equals the new NMI of 1.5 kg/day, and weight loss ceases. No amount of continued GLP-1 agonism can overcome this physical reality. Only by increasing k – the mass clearance coefficient itself – can NMO be maintained or elevated as body mass declines, thereby extending the duration and magnitude of weight loss

The therapeutic implication is clear. An intervention that targets only NMI leaves NMO free to decline through two independent mechanisms – passive (Torricelli’s Law) and active (k down-regulation). To overcome the plateau, both sides of the mass balance equation must be addressed simultaneously.

3. The Hypothesis: Dual-Action MBM Pharmacotherapy

I hypothesize that the optimal anti-obesity pharmacotherapy consists of two agents with complementary mechanisms of action, chosen specifically to target both sides of the mass balance equation. This MBM-based approach differs fundamentally from current combination strategies, such as tirzepatide (GIP/GLP-1 dual agonism) or CagriSema (semaglutide + cagrilintide). These combinations target two overlapping mechanisms of NMI reduction – appetite suppression via different receptor pathways – but remain entirely on one side of the mass balance equation. The plateau persists because NMO is never addressed. The present hypothesis proposes a truly orthogonal combination: one agent that reduces mass inflow, and another that prevents the adaptive decline in mass outflow.

- Component A (NMI Reduction): An agent that reduces net mass inflow, primarily through central appetite suppression and/or delayed gastric emptying.

- Component B (NMO Stabilization or Enhancement): An agent that prevents the adaptive decline in the mass clearance coefficient k or actively increases k, thereby maintaining or accelerating mass outflow even as body mass declines.

This hypothesis generates several testable predictions:

1. The combination will produce greater total weight loss than Component A alone, with a later-occurring and lower-magnitude plateau.

2. The combination will yield more favorable body composition (greater lean mass retention relative to fat loss) by sparing lean tissue catabolism.

3. The combination will blunt or eliminate the early decline in resting energy expenditure seen with GLP-1 monotherapy.

4. The mass clearance coefficient k will remain stable or increase under dual therapy, whereas it declines under monotherapy

4. Candidate Agents for Component B (NMO Stabilization)

I identify three classes of agents with the mechanistic potential to stabilize or enhance NMO. All three have existing safety and efficacy data in humans, making them immediately viable candidates for combination trials.

4.1. Mitochondrial Uncouplers: Increasing Basal k

Mitochondrial uncoupling proteins (UCPs), particularly UCP1 in brown adipose tissue (BAT), dissipate the proton gradient across the inner mitochondrial membrane, generating heat instead of ATP [9]. In MBM terms, mitochondrial uncoupling increases k: it accelerates the oxidation of carbon substrates to CO₂ without producing useful chemical work, thereby increasing NMO for a given body mass.

The historical uncoupler 2,4-dinitrophenol (DNP) produced dramatic weight loss but was abandoned due to a narrow therapeutic window. However, next-generation controlled-release mitochondrial uncouplers and liver-targeted prodrugs, such as HU6 and BAM15, are currently in early-phase clinical development and show promise for reactivating BAT and increasing resting energy expenditure without DNP’s toxicity [10,11].

4.2. SGLT2 Inhibitors: Mass Loss Through Glucosuria

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, widely used in type 2 diabetes, block renal glucose reabsorption, causing urinary glucose excretion of approximately 60–100 g/day in patients with hyperglycemia [12]. In MBM terms, this is a direct, pharmacologically induced increase in NMO: carbon mass that would otherwise have been retained is excreted.

Furthermore, SGLT2 inhibitors shift substrate oxidation toward fat utilization and have been shown to increase resting energy expenditure modestly [13]. Their combination with GLP-1 agonists (e.g., semaglutide + empagliflozin) has demonstrated additive effects on weight loss in small trials, consistent with MBM predictions [14].

The glucosuria induced by SGLT2 inhibition represents an increase in NMO of approximately 60–100 g/day of carbon-containing mass. For a 100-kg individual with a baseline k of 0.20 kg^0·5/day (NMO ≈ 2.0 kg/day), this corresponds to a roughly 3–5% increase in NMO. While modest in isolation, this increase is sufficient to offset the early-phase decline in k that normally accompanies GLP-1 monotherapy, thereby delaying or preventing the plateau.

4.3. Activin/Myostatin Pathway Inhibitors: Preserving Lean Mass

The activin receptor (ActRII) signaling pathway negatively regulates skeletal muscle mass. Inhibition of this pathway – via agents such as bimagrumab (a monoclonal antibody against ActRII) or novel orally bioavailable receptor traps – has been shown to increase lean mass and reduce fat mass simultaneously [15]. In MBM terms, these agents improve nitrogen balance, directing dietary protein mass toward lean tissue accretion rather than oxidative disposal.

This mechanism is particularly valuable in the context of GLP-1-induced weight loss, where a significant fraction of the lost mass can be lean tissue. The Phase 2 BELIEVE trial demonstrated that bimagrumab added to semaglutide resulted in significantly greater fat loss and lean mass preservation than semaglutide alone [16].

4.4. Prioritization of Component B Agents

The three classes of agents discussed above differ in their stage of development, safety profile, mechanistic complementarity with GLP-1/GIP agonists, and readiness for near-term clinical combination trials. Based on these criteria, I propose the following prioritization for Component B (NMO stabilization or enhancement):

1. SGLT2 inhibitors (e.g., empagliflozin or dapagliflozin) represent the most immediately actionable option. They are already approved, have well-characterized safety profiles, and can be combined with tirzepatide or semaglutide using existing regulatory pathways. Their direct induction of glucosuria provides a measurable increase in NMO that is orthogonal to appetite suppression, while their promotion of fatty acid oxidation offers additional metabolic synergy and lean mass sparing potential.

2. Activin/myostatin pathway inhibitors (e.g., bimagrumab or next-generation ActRII receptor traps) rank second due to their unique ability to improve body composition. By preserving or even increasing lean mass during caloric deficit, these agents address one of the major limitations of GLP-1-based monotherapy and may indirectly support a higher mass clearance coefficient k through maintenance of metabolically active tissue.

3. Mitochondrial uncouplers (e.g., HU6, BAM15 and related compounds) offer the greatest theoretical potential for robustly increasing k via enhanced substrate oxidation and thermogenesis. Although still in early clinical development, they represent the most direct pharmacological mimic of adaptive thermogenesis reversal. Once safety and dosing are optimized, they could deliver the largest incremental effect on NMO.

This prioritized, stepwise approach allows rapid clinical testing of the MBM hypothesis while balancing translational feasibility with long-term therapeutic upside.

5. Proposed MBM-Optimized Combination and Clinical Rationale

Integrating the above analysis, I propose the following as the leading MBM-optimized combination for near-term clinical investigation:

- Component A: Tirzepatide (GIP/GLP-1 dual agonist) or semaglutide (GLP-1 agonist), chosen for their potent and well-characterized NMI-reducing effects.

- Component B: Empagliflozin or dapagliflozin (SGLT2 inhibitor), chosen for their ability to increase NMO via glucosuria, their favorable safety profile, and their existing regulatory approval.

This combination directly targets the two components of the mass balance equation:

- Tirzepatide/Semaglutide reduces NMI by suppressing appetite and delaying gastric emptying.

- Empagliflozin/Dapagliflozin increases NMO by inducing urinary carbon loss (glucosuria) and shifting substrate oxidation toward fat.

The MBM predicts that this combination will produce a significantly larger total weight loss than either agent alone, with a delayed or absent plateau, and with greater preservation of lean mass due to the SGLT2 inhibitor’s promotion of fatty acid oxidation over amino acid catabolism.

6. Implications for Drug Development Research

If validated, this MBM-based rational polypharmacy framework has significant implications for the future of obesity pharmacotherapy. First, it provides a principled, physics-based method for selecting drug combinations, moving the field beyond the current trial-and-error approach of combining any two agents that happen to show efficacy individually. Second, it identifies the mass clearance coefficient k as a novel endpoint for early-phase clinical trials, enabling rapid assessment of whether a candidate agent is genuinely enhancing NMO. Third, it suggests that future drug discovery should specifically target mechanisms that increase k – a therapeutic direction that has received minimal attention under the EBM paradigm.

The following outlines a potential research direction for testing the hypothesis and does not constitute a prescriptive clinical trial protocol. As a concrete next step, I propose a four-arm randomized controlled trial comparing (1) semaglutide monotherapy, (2) empagliflozin monotherapy, (3) semaglutide + empagliflozin combination, and (4) placebo, with the primary endpoint being the change in k from baseline to week 52, measured via the protocol described by Arencibia-Albite [17]. Secondary endpoints would include total weight loss, body composition (DXA), and resting energy expenditure (indirect calorimetry). Such a trial would provide the first direct test of whether an NMO-targeting agent can prevent the adaptive decline in mass clearance that limits current therapy.

7. Conclusions

The obesity pharmacotherapy revolution has hit a plateau – not in enthusiasm or investment, but in the biological response to single-agent NMI-reducing therapy. The mass balance model explains why this plateau is inevitable and, more importantly, how it can be overcome. By targeting both sides of the mass balance equation – reducing NMI with a GLP-1-based agent and stabilizing or enhancing NMO with an SGLT2 inhibitor, mitochondrial uncoupler, or myostatin pathway inhibitor – we can rationally design combination therapies that transcend the limits of current monotherapy. Billions of dollars are currently being invested in refining appetite suppression alone; the MBM suggests that the next great leap in efficacy will come not from further reducing mass inflow, but from finally turning our attention to the neglected side of the equation: mass outflow.

The framework presented here may serve as a conceptual basis for future clinical trials designed to test MBM-based combination strategies. The goal of such research would not simply be to develop another appetite suppressant, but to explore whether a pharmacotherapy addressing the fundamental physics of mass flow dysregulation can deliver more substantial and durable weight loss than current approaches.

Translational Disclaimer

This article presents a mechanistic hypothesis grounded in the physics-based mass balance model. It is intended exclusively as a conceptual framework to inform and stimulate future clinical research. The drug combinations discussed are strictly investigational and are emphatically not presented as therapeutic recommendations for current clinical practice. All clinical decisions must be guided by regulatory approvals, evidence-based guidelines, and the judgment of qualified healthcare professionals.